Gilead Sciences CEO and Leadership

Merdad Parsey, MD, PhD is Gilead’s Chief Medical Officer, responsible for overseeing the company’s global clinical development and medical affairs organizations. In his role, Merdad supervises all clinical trials and development operations. Together with the leadership team, he works to advance clinical development strategies and programs with the goal of changing the trajectory of disease, and transforming care for the patients of today and tomorrow.

Merdad joined Gilead in 2019, after serving as Senior Vice President of Early Clinical Development at Genentech, where he led clinical development for areas including inflammation, oncology and infectious diseases. Prior to Genentech, Merdad served as President and CEO of 3-V Biosciences (now Sagimet BioSciences), held development roles at Sepracor, Regeneron and Merck and was Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine.

He completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

Merdad currently serves on the Board of Directors for Sagimet BioSciences.

Mr. Dickinson joined Gilead in 2016 and has transformed the way that the company approaches corporate development, expanding the kinds of transactions executed and implementing a broader and more strategic approach to deal-making. He served as the architect of the company’s 2017 acquisition of Kite Pharma, Inc. and of the 10-year, global research collaboration with Galapagos NV announced earlier this year. In his new role, Mr. Dickinson will retain responsibility for the corporate development and strategy organization.

Johanna Mercier is a Chief Commercial Officer at GILEAD SCIENCES INC and is based in Foster City, California. She has worked as President, US & large markets at BRISTOL MYERS SQUIBB CO. Johanna attended Montréal (Québec between 1987 and 1990 and Concordia Univeristy between 1993 and 1996.

Daniel O'Day serves as Chief Operating Officer of Pharmaceuticals at Roche Holding AG. O'Day serves as the Chief Operating Officer of Roche Diagnostics GmbH and Hoffmann-La Roche Ltd. O'Day served as the Chief Executive Officer and President of Roche Molecular Diagnostics at Roche Carolina Inc. and Roche Holding AG. He served as the Chief Operating Officer of Roche Pharma AG since September 1, 2012. O'Day served as the Chief Executive Officer and President of Roche Diagnostics GmbH. O'Day was with Roche for more than 20 years, following positions of increasing responsibility in sales, marketing, and human resources. He began his career in 1987 at Roche in the U.S. Pharmaceuticals organization in Sales and Marketing. Afterwards, he held various positions in Roche Pharma in Switzerland, Japan, and Denmark. In 2006 O'Day joined Roche Diagnostics and became Head of the Business Area Molecular Diagnostics. On January 1 2010 he was appointed as Chief Operating Officer for Roche's global diagnostics business. He worked 11 years managing international assignments that included life cycle leadership at Roche Pharmaceuticals in Basel, Switzerland; strategic planning and involvement in the Chugai merger in Tokyo, Japan; and, prior to joining the molecular diagnostics unit, served as General Manager of Roche Pharmaceuticals in Denmark. He has been a Director of Chugai Pharmaceutical Co. Ltd. since March 27, 2013. He serves as a Director of Genentech, Inc. and California Healthcare Institute. O'Day holds an undergraduate degree in Biology from Georgetown University and a Master of Business Administration from Columbia University.